13th Annual Business of Biosimilars and Generic Drugs agenda now available

After years of waiting, in which your business came ever closer to the “patent cliff,” the FDA has released its long-awaited user fee structure and draft guidelines for the development and regulatory approval of biosimilars in the United States.

The 13th Annual Business of Biosimilars and Generic Drugs event is designed to help you focus on the most significant new points in these guidelines and further accelerate what indeed promises to be a significantly abbreviated path to approval for your follow-on biologics.  It will take place September 10-12, 2012 in Boston, MA.

No other event focuses so sharply on eliminating the obstacles you face in the commercialization of your next biosimilar candidate. This year we are particularly proud to feature time-sensitive updates on the biggest news now facing the industry!

What is featured in this year’s Business of Biosimilars and Generic Drugs event?

• - FDA Regulatory Updates
• - Strategic Partnerships
• - Learning the right market lessons from generic drugs

Download the complete 2012 program here.

Share this article with your social network, just click below to share now!

Share |

Limited time offer to attend the 2nd Annual Business of Biosimilars

As a reader of Future of Biopharma, we'd like to extend to you a special offer. For five days only you will have the opportunity to save $700 off the standard registration rate at the 2nd Annual Business of Biosimilars Conference. This WEB ONLY offer is valid THROUGH MONDAY, JULY 26th. Please use code XP1586WEB to receive this discount. That's a Savings of $700 for a 3 day pass!

We know that this has been a tough year to get approval to attend events, but there's only ONE event your industry, key partners AND competitors will be at this year...Business of Biosimilars in September in Boston. In addition to saving $700 when you register through this offer, you will get access to a full day seminar on Strategies to Expedite Approval of Your Follow-On Biologic: From Drug Discovery to Post Approval, a dinner workshop on IP Protection and Patent Litigation, and over 30 expert faculty members including representatives from Sandoz, Biogen IDEC Inc., Hospira, Sanofi-Aventis, the FTC and much more.

Visit the webpage here to find out more information on the speakers and topics of this event:
http://bit.ly/cA9IaI

Share this article with your social network, just click below to share now!

Share |

Quality Safety and Efficacy of Follow-on Biologics

Teruhide Yamaguchi posted this sideshow titled "Quality Safety and Efficacy of Follow-on Biologics." It looks at the state of biosimilars in the EU, US and Japanese markets.


Quality Safety and Efficacy of Follow-on Biologics -

Share this article with your social network, just click below to share now!

Share |

2nd Annual Business of Biosimilars: New Dates & Venue Announced for 2010

September 20-22, 2010

Hyatt Regency Boston • Boston, MA

The biopharmaceutical market is at a crossroads. Some of the biggest-selling biologics are losing their patent protection, opening up a global market estimated at over $19 billion for biosimilars, otherwise known as “follow-on biologics” or “biogenerics”. Already we are seeing changing business models as a whole new set of global competitors emerges. As the industry moves forward, it asks itself:

*What will the new biosimilars market look like?
*How do you navigate regulatory challenges?
*Who can you partner with to leverage your company?
*What product launch and marketing strategies should you use?
*How do you ensure your economic success?

IIR’s 2nd Annual Business of Biosimilars conference delivers the tools you need to succeed in the biosimilar arena. Exchange ideas and best practices surrounding innovation, regulatory change, IP protection and patent litigation strategies, and commercial management.

Join leaders and industry experts to develop effective strategies to navigate scientific, regulatory, economic, and legal challenges to remain competitive in commercializing your biosimilar portfolio in the United States and abroad.

Do You Want Your Message To Reach Top Level Decision Makers?
To learn about how you can position your company as a leader and innovator through a custom sponsorship package, please contact Andrew Sinetar at 646.895.7472 or email asinetar@iirusa.com.

Share this article with your social network, just click below to share now!

Share |